You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Activated-B-Cell DLBCL

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Activated B-cell DLBCL (ABC DLBCL) Trial in United Kingdom, United States (Acalabrutinib)

Active, not recruiting
Has Results
  • Activated B-cell Diffuse Large B-Cell Lymphoma (ABC DLBCL)
  • Los Angeles, California
  • +6 more
Dec 1, 2022

B-ALL, DLBCL, B ALL Trial in New York (131-I Apamistamab, CAR T-cell)

Recruiting
  • B-ALL
  • +10 more
  • 131-I Apamistamab
  • CAR T-cell
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Mar 7, 2022

Non-Hodgkin's Lymphoma (NHL), Activated B-Cell Type DLBCL (ABC-DLBCL), Mantle Cell Lymphoma (MCL) Trial in Indianapolis, Spokane

Recruiting
  • Non-Hodgkin's Lymphoma (NHL)
  • +4 more
  • Indianapolis, Indiana
  • +1 more
Jul 12, 2022

Diffuse Large B Cell Lymphoma (DLBCL) Trial in Toronto (glofitamab)

Not yet recruiting
  • Diffuse Large B Cell Lymphoma (DLBCL)
  • Toronto, Ontario, Canada
    Princess Margaret Cancer Centre
Sep 18, 2023

DLBCL Trial in Jinan (Mitoxantrone Hydrochloride Liposome Injection)

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma
  • Mitoxantrone Hydrochloride Liposome Injection
  • Jinan, Shandong, China
    Affiliated Cancer Hospital of Shandong First Medical University
May 16, 2023

Treatment of Diffuse Large B Cell Lymphoma - BRA-DLBCL

Recruiting
  • Diffuse Large B Cell Lymphoma
    • Salvador, Bahia, Brazil
    • +9 more
    Jul 24, 2023

    DLBCL, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma Trial in Minneapolis (E7777)

    Recruiting
    • DLBCL
    • +3 more
    • Minneapolis, Minnesota
      University of Minnesota, Masonic Cancer Center
    Jul 1, 2022

    Costs of CAR-T Therapies in Diffuse Large B-cell Lymphoma:

    Completed
    • Diffuse Large B-cell Lymphoma
      • East Hanover, New Jersey
        Novartis
      Jun 16, 2023

      Diffuse Large B Cell Lymphoma Trial in Tampa (Itacitinib, Chimeric antigen receptor (CAR) T-cell therapy)

      Recruiting
      • Diffuse Large B Cell Lymphoma
      • Itacitinib
      • Chimeric antigen receptor (CAR) T-cell therapy
      • Tampa, Florida
        Moffitt Cancer Center
      Mar 6, 2023

      DLBCL - Diffuse Large B Cell Lymphoma, Lymphoma Trial in Shanghai (Other)

      Not yet recruiting
      • DLBCL - Diffuse Large B Cell Lymphoma
      • Lymphoma
      • Other
      • Shanghai, Shanghai, China
        Ruijin Hospital, Shanghai Jiao Tong University School of Medicin
      Sep 6, 2023

      Diffuse Large B Cell Lymphoma | DLBCL Recurrent/Refractory Trial (ZR2-ICE)

      Not yet recruiting
      • Diffuse Large B Cell Lymphoma | Diffuse Large B-Cell Lymphoma Recurrent/Refractory
      • (no location specified)
      Sep 5, 2023

      DLBCL - Diffuse Large B Cell Lymphoma, Follicular Lymphoma Trial in Xiamen (Lenalidomide combined with G-CHOP (LO CHOP))

      Recruiting
      • DLBCL - Diffuse Large B Cell Lymphoma
      • Follicular Lymphoma
      • Lenalidomide combined with G-CHOP (LO CHOP)
      • Xiamen, Fujian, China
        Bing Xu
      Nov 28, 2023

      Frontline of ASCT in High-risk DLBCL

      Recruiting
      • Diffuse Large B Cell Lymphoma
        • Beijing, Beijing, China
          Peking University People's Hospital
        Apr 26, 2023

        DLBCL Trial (Acalabrutinib, Rituximab)

        Not yet recruiting
        • Diffuse Large B-Cell Lymphoma
        • (no location specified)
        Jul 11, 2023

        Diffuse Large B Cell Lymphoma,DLBCL Trial in Chengdu (PM 8.4 mg/m2, PM 11.2 mg/m2)

        Recruiting
        • Diffuse Large B Cell Lymphoma，DLBCL
        • PM 8.4 mg/m2
        • PM 11.2 mg/m2
        • Chengdu, Sichuan, China
          West China Hospital Sichuan University
        Jan 15, 2023

        Diffuse Large B-cell Lymphoma Recurrent, Diffuse Large B Cell Lymphoma Refractory Trial in Hangzhou (Anlotinib HCl, Rituximab,

        Recruiting
        • Diffuse Large B-cell Lymphoma Recurrent
        • Diffuse Large B Cell Lymphoma Refractory
        • Anlotinib hydrochloride, Rituximab, gemcitabine, oxaliplatin
        • Hangzhou, Zhejiang, China
          Zhejiang Cancer Hospital
        Oct 12, 2023

        Including miRNA-based Tumor Signatures in Diffuse Large B Cell

        Not yet recruiting
        • Diffuse Large B Cell Lymphoma
        • Relapsed Non-Hodgkin Lymphoma
        • no intervention (observational study)
        • Napoli, Italy
        • +2 more
        Feb 17, 2023

        Lymphomas Non-Hodgkin's B-Cell Trial in Ballarat, Box Hill, Heidelberg (Avelumab)

        Active, not recruiting
        • Lymphomas Non-Hodgkin's B-Cell
        • Ballarat, Victoria, Australia
        • +2 more
        Jan 30, 2023

        DLBCL - Diffuse Large B Cell Lymphoma Trial in Toronto (Cyclophosphamide, TLI)

        Recruiting
        • DLBCL - Diffuse Large B Cell Lymphoma
        • Toronto, Ontario, Canada
          Princess Margaret Cancer Centre
        Jul 19, 2023

        Relapsed or Refractory B-cell Lymphoma Trial in Shanghai (SR-GDP)

        Not yet recruiting
        • Relapsed or Refractory B-cell Lymphoma
        • Shanghai, Shanhai, China
          Ruijin Hospital
        Sep 29, 2023

        Diffuse Large B-cell Lymphoma (DLBCL) Trial in Lanzhou (Zanubrutinib)

        Not yet recruiting
        • Diffuse Large B-cell Lymphoma (DLBCL)
        • Lanzhou, Gansu, China
          The First Hospital of Lanzhou University
        Oct 23, 2022

        Diffuse Large B-cell Lymphoma Trial in Hangzhou (Metabolically Armed CD19 CAR-T cells)

        Recruiting
        • Diffuse Large B-cell Lymphoma
        • Metabolically Armed CD19 CAR-T cells
        • Hangzhou, Zhejiang, China
          The first affiliated hospital of medical college of zhejiang uni
        Nov 1, 2023

        Diffuse Large B Cell Lymphoma Trial in Shenyang (Zanubrutinib, Rituximab, Cyclophosphamide)

        Not yet recruiting
        • Diffuse Large B Cell Lymphoma
        • Shenyang, Liaoning, China
          Xing Xiaojing
        Jun 1, 2023

        Diffuse Large B Cell Lymphoma, DLBCL, Cancer Trial in Madison (Rituximab, Cyclophosphamide, Doxorubicin)

        Recruiting
        • Diffuse Large B Cell Lymphoma
        • +2 more
        • Madison, Wisconsin
          University of Wisconsin Carbone Cancer Center
        Dec 12, 2022

        DLBCL (DLBCL) Trial (Tisagenlecleucel)

        Withdrawn
        • Diffuse Large B-Cell Lymphoma (DLBCL)
        • Tisagenlecleucel
        • (no location specified)
        Feb 25, 2022